Johnson says he won't concede on parents proxy voting battle
Digest more
Top News
Impacts
ABC News |
With the House of Representatives at a standstill, Speaker Mike Johnson is refusing to fold on his strong opposition to allowing new parents in Congress to vote remotely. "I don't concede on somethi...
The New York Times |
Speaker Mike Johnson’s failed effort this week to shut down a bipartisan bid to allow new parents in Congress to vote remotely after the birth of a child highlighted the limits of his power and intens...
Read more on News Digest
One big reason the Dow Jones Industrial Average slipped Tuesday had little to do with tariffs. Johnson & Johnson's stock tumbled 6.5% after a [bankruptcy judge dismissed](
Johnson & Johnson (NYSE: JNJ) today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit within Johnson & Johnson Innovative Medicine.
Johnson & Johnson’s plan to settle thousands of talc-related lawsuits through bankruptcy was shot down in court.
Tesla stock rises after ending the first quarter down 36%, its worst first quarter on record, and Johnson & Johnson tumbles after its latest talc resolution is rejected by a judge.
Nearly a year after a jury decided that Johnson & Johnson should be fined just over $150 million in a lawsuit alleging that the company engaged in misleading marketing tactics for two of its HIV meds, a judge has upped the penalty more than tenfold.
Dwayne "The Rock" Johnson was on his way to Houston for the opening of the United Football League's second season when his pilot informed him he must return to Hawaii for everyone's safety.
Traditional defensive stocks Johnson & Johnson, United Health, and Procter & Gamble are all up and helping to keep the S&P 500’s dropoff from greater severity. The aforementioned companies also have recent positive news to justify their positive upticks.
Johnson & Johnson's long-term prospects are promising due to strong drug pipeline developments and significant R&D investments. Read what could be next for shares in this healthcare giant.